中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
18期
22-23
,共2页
慢性粒细胞白血病%伊马替尼%三尖杉酯碱
慢性粒細胞白血病%伊馬替尼%三尖杉酯堿
만성립세포백혈병%이마체니%삼첨삼지감
Chronic myeloid leukemia%Imatinib%Three harringtonine
目的 观察伊马替尼方案治疗慢性粒细胞白血病(CML)的疗效.方法 将86例慢性粒细胞白血病患者随机分为两组,治疗组(50例)采用伊马替尼治疗,对照组(36例)采用三尖杉酯碱治疗.并比较两组治疗后血液学缓解率和细胞遗传学缓解率.结果 治疗组完全血液学缓解率和主要细胞遗传学缓解率均高于对照组(P＜0.05),两组不良反应轻微.结论 伊马替尼治疗与三尖杉酯碱治疗相比,可显著提高CML患者的血液学和细胞遗传学缓解率,从而延长患者生存期.
目的 觀察伊馬替尼方案治療慢性粒細胞白血病(CML)的療效.方法 將86例慢性粒細胞白血病患者隨機分為兩組,治療組(50例)採用伊馬替尼治療,對照組(36例)採用三尖杉酯堿治療.併比較兩組治療後血液學緩解率和細胞遺傳學緩解率.結果 治療組完全血液學緩解率和主要細胞遺傳學緩解率均高于對照組(P＜0.05),兩組不良反應輕微.結論 伊馬替尼治療與三尖杉酯堿治療相比,可顯著提高CML患者的血液學和細胞遺傳學緩解率,從而延長患者生存期.
목적 관찰이마체니방안치료만성립세포백혈병(CML)적료효.방법 장86례만성립세포백혈병환자수궤분위량조,치료조(50례)채용이마체니치료,대조조(36례)채용삼첨삼지감치료.병비교량조치료후혈액학완해솔화세포유전학완해솔.결과 치료조완전혈액학완해솔화주요세포유전학완해솔균고우대조조(P＜0.05),량조불량반응경미.결론 이마체니치료여삼첨삼지감치료상비,가현저제고CML환자적혈액학화세포유전학완해솔,종이연장환자생존기.
Objective To observe the effect of imatinib on patients with chronic myeloid leukemia.Methods Eighty patients with chronic myeloid leukemia were randomly divided into two groups,the treatment group (50 cases) and the control group (36 cases).Patients in the treatment group were treated with imatinib,while the patients in the control group were treated with three harringtonine.The response rates of hematology and cytogene were compared after treatment.Results The complete response rate of hematology and the key response rate of cytogene in the treatment group were higher than those in the control group (P ＜ 0.05).Conclusions Compared with three harringtonine,imatinib an improve the complete response rate of hematology and the key response rate of cytogene which could extend patients survival.
